Summary
Healios K.K. (4593) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Healios K.K. ever had a stock split?
Healios K.K. Profile
| Biotechnology Industry | Healthcare Sector | Tadahisa S. Kagimoto CEO | JPX Exchange | JP3835100003 ISIN |
| JP Country | 65 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Healios K.K. is a prominent entity in the biomedical sector, focusing on pioneering advancements in cell therapy and regenerative medicine. The company engages in extensive activities encompassing the research and development, manufacture, and distribution of innovative medical solutions across Japan, Europe, and the United States. Initially established under the name Retina Institute Japan, K.K., it underwent a name change to Healios K.K. in September 2013, marking a new chapter in its mission to address a range of medical conditions through cutting-edge therapy options. Since its inception in 2011, Healios K.K. has positioned itself at the forefront of regenerative medicine, operating from its headquarters in Tokyo, Japan.
Products and Services
Healios K.K. boasts a diversified portfolio of therapeutic products aimed at addressing significant unmet medical needs, including:
- HLCM051 for Ischemic Stroke and Acute Respiratory Distress Syndrome (ARDS): This therapy is designed to provide treatment for ischemic stroke, a condition caused by a blockage in blood flow to the brain, and ARDS, a type of severe lung failure. HLCM051 works by enhancing the body’s natural healing processes, potentially offering significant improvements in patient outcomes.
- HLCN061 for Treating Solid Tumors: Representing a leap in oncology, HLCN061 is aimed at the treatment of solid tumors. This innovative therapy seeks to leverage the power of cell therapy to target and eradicate cancer cells, offering a new hope for patients with various forms of solid tumors.
- HLCR011 for the Treatment of Retinal Pigment Epithelium Tear and Age-related Macular Degeneration: Age-related macular degeneration (AMD) and retinal pigment epithelium tears are major causes of vision loss. HLCR011 is engineered to repair and regenerate the damaged ocular tissues, potentially restoring vision or halting the progression of these debilitating eye conditions.
- HLCL041 for Liver Disease: This cell therapy product is tailored to combat liver diseases, aiming to regenerate damaged liver tissue or offer supportive therapies in conditions where liver function is compromised. HLCL041 embodies Healios K.K.'s commitment to extending regenerative medicine's reach to organ-specific conditions, highlighting the company's versatile approach to healing.
